Carbon nanohorns allow acceleration of osteoblast differentiation via macrophage activation. by Hirata, Eri (author) et al.
Nanoscale
PAPER
Cite this: Nanoscale, 2016, 8, 14514
Received 4th April 2016,
Accepted 27th June 2016
DOI: 10.1039/c6nr02756c
www.rsc.org/nanoscale
Carbon nanohorns allow acceleration of
osteoblast diﬀerentiation via macrophage
activation†
Eri Hirata,*a Eijiro Miyako,b Nobutaka Hanagata,c Natsumi Ushijima,d
Norihito Sakaguchi,e Julie Russier,f Masako Yudasaka,b,g Sumio Iijima,g
Alberto Biancof and Atsuro Yokoyamaa
Carbon nanohorns (CNHs), formed by a rolled graphene structure and terminating in a cone, are promis-
ing nanomaterials for the development of a variety of biological applications. Here we demonstrate that
alkaline phosphatase activity is dramatically increased by coculture of human monocyte derived macro-
phages (hMDMs) and human mesenchymal stem cells (hMSCs) in the presence of CNHs. CNHs were
mainly localized in the lysosome of macrophages more than in hMSCs during coculturing. At the same
time, the amount of Oncostatin M (OSM) in the supernatant was also increased during incubation with
CNHs. Oncostatin M (OSM) from activated macrophage has been reported to induce osteoblast diﬀeren-
tiation and matrix mineralization through STAT3. These results suggest that the macrophages engulfed
CNHs and accelerated the diﬀerentiation of mesenchymal stem cells into the osteoblast via OSM release.
We expect that the proof-of-concept on the osteoblast diﬀerentiation capacity by CNHs will allow future
studies focused on CNHs as ideal therapeutic materials for bone regeneration.
Introduction
Bone fractures, osteoarthritis, osteoporosis or bone cancers
represent common and serious clinical problems. The man-
agement and reconstruction of damaged or diseased bone
tissues is still an important global healthcare challenge to
improve the lives of the patients in order to recover their
normal functions and health.1
Carbon nanomaterials, such as carbon nanotubes (CNTs),
graphene and carbon nanohorns (CNHs), have been studied
for biomedical applications because of their unique
characteristics.2–11 Carbon nanomaterials are promising candi-
dates for bone tissue engineering applications due to their
superior cytocompatible, mechanical and electrical
properties.12–18 Some years ago we initiated a program on the
applications of carbon nanomaterials for bone tissue regener-
ation. We have reported that CNT-coated substrates can be
eﬀective for the adhesion and diﬀerentiation of osteoblasts,
while CNT-coated collagen sponges resulted in possessing a
favorable biocompatibility profile with bone.19–22 On the other
hand, the impurities (e.g. metal catalysts and amorphous
carbons) and the high aspect ratio of CNTs might lead to con-
cerns about their safety for clinical uses.23,24
There is currently a great interest in creating biomedical
applications using CNHs,25–27 owing to their advantages, such
as low toxicity and huge inner nanospaces for drug
loading.28,29 We previously found that CNHs promoted bone
formation within a period of 2 weeks.25 More interestingly, we
observed that a high amount of CNHs was localized inside the
macrophages around the newly formed bone.25 However, the
mechanism of bone formation by CNHs has not been clarified
yet. Therefore, in this study, we focused our attention on the
eﬀect of macrophages loaded with CNHs on osteoblast diﬀer-
entiation. Several studies have reported that immune cells
including monocytes and macrophages are key players in bone
tissue integration with various biomaterials.30 We hypoth-
esized that CNHs will be able to stimulate the macrophages
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for the production of osteoinductive factors such as cytokines,
which are necessary for the diﬀerentiation of hMSCs into
osteoblasts and the formation of new bone. Nicolaidou et al.
reported thatmonocytes/macrophages cultured on human bone
marrow-derived mesenchymal stem cells directly and potently
induced hMSC diﬀerentiation into osteoblasts.31 On the basis
of these findings, in this study, hMDMs were cultured with
hMSCs in the presence of CNHs, in order to elucidate the
eﬀect of CNHs on macrophages for the diﬀerentiation of the
stem cells into osteoblasts. First, the influence and localization
of CNHs into hMDMs were investigated. The increase in the
amount of alkaline phosphatase (ALP) activity from cocultur-
ing hMDMs and hMSCs with CNHs was assessed. In addition,
we evidenced that the expression of Oncostatin M (OSM), a
multifunctional cytokine that induces osteoblast diﬀeren-
tiation and matrix mineralization, increased in the presence of
CNHs.32 The obtained results show more accurately how CNHs
can influence the formation of new bone.
Results
In order to clearly observe the cellular uptake of CNHs during
the coculture of hMSCs and hMDMs, stem cells, labelled with
CMPTX dye, and the macrophages were cultured with CNHs
functionalized with fluorescent Alexa488-BSA (Alexa-BSA-CNHs)
for 24 hours (Fig. 1). During cell culturing with increasing con-
centrations of CNHs, we observed that 50 µg mL−1 (the highest
dose used) of CNHs was extensively aggregated in the culture
medium. So we decided to use 5 µg mL−1 of CNHs for the sub-
Fig. 1 Confocal laser microscopy images of Alexa-BSA-CNHs. Fluorescent (green) CNHs were added to only hMSCs (A–C), only hMDMs (D–F) and
to their cocultures (G–I). hMSCs were stained with the Cell Tracker Red CMPTX dye. (A, D and G) Cells were observed with the ﬁlter for Alexa488.
(B, E and H) Cells were observed with the ﬁlter for CMPTX dye. (C, F and I) Merged images.
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sequent experiments. CNHs at 5 µg mL−1 remained well dis-
persed for 7 days in cell culture media. The confocal
microscopy images showed that very few Alexa-BSA-CNHs were
present inside the hMSCs. There were significantly low levels
of fluorescence from Alexa-BSA-CNHs in these cells (Fig. 1A–C).
On the other hand, most of the hMDMs were able to internalize
a large number of fluorescent Alexa-BSA-CNHs (Fig. 1D–F).
More interestingly, we could observe that high amounts of
Alexa-BSA-CNHs were also present inside the hMDMs in com-
parison with hMSCs under coculturing conditions (Fig. 1G–I).
To further observe the presence of CNHs in these two types
of cells, the cellular uptake behavior of CNHs after coculturing
for 24 hours was analyzed by TEM (Fig. 2). Many CNHs were
clearly observed in the hMDMs that were in close contact with
the hMSCs (Fig. 2B). The morphology and structure of the cells
were not aﬀected compared to the control cells without CNHs
(Fig. 2A). Most of the macrophages were in close contact with
stem cells (Fig. 2C and D). We observed many CNHs in the cyto-
plasmic vesicles. In the lysosomes and the endosomes, CNHs
taken up by hMDMs preserved their globular structures
(Fig. 2E), similar to control CNHs (Fig. 2F). After 7 days of cocul-
turing, CNHs mainly remained inside the hMDMs (Fig. S1†).
Next, hMDMs were incubated with diﬀerent concentrations
of CNHs (0.5, 5.0, 50 µg mL−1) for 24 hours to explore the
eﬀect of CNHs on the cellular viability of human macrophages.
At the end of the incubation time, the cells were stained with
AnnV and PI to determine the cell viability (Fig. 3). CNHs did
not cause any significant necrosis or apoptosis at any concen-
trations compared with the untreated cells. The quantity of
CD86, a co-stimulatory molecule expressed by macrophages
upon activation,28 was not aﬀected at the diﬀerent concen-
trations of CNHs tested (Fig. S2†).
In order to explore cell response to CNHs by gene
expression, microarray analysis was carried out after culturing
hMDMs with CNHs for 24 hours. We identified 30 modified
genes in hMDMs treated with CNHs. We identified 30 diﬀeren-
tially expressed genes whose fold-change represented by the
logarithmic ratio (log2 ratio) to the expression level of the
control was more than 1 (>1) and less than −1 (<−1). Of these
30 altered genes, 16 were up-regulated and 14 were down-
regulated genes (Table 1). By classifying these genes into the
Gene Ontology (GO) Biological Process category, we obtained 5
statistically significant (p < 1 × 10−5) GO terms that are related
to lymphocyte migration from the CNH up-regulated genes
(Table 2). On the other hand, no GO terms were obtained from
the CNH down-regulated genes. The up-regulated genes classi-
fied into the lymphocyte migration related GO terms included
genes that encode chemokines like CCL3, CCL4 and CXCL12
(Table 2). The expression levels of these chemokine-related
genes were also analyzed by real time RT-PCR, and this analysis
verified the upregulation in hMDMs treated with CNHs (Fig. 4).
ALP is one of the osteoblastic diﬀerentiation markers at the
early stages. After 7 days, ALP activity was higher in the cocul-
tured hMSCs and hMDMs both with and without CNHs com-
pared with those of MSCs alone. Moreover ALP activity in
cocultures is dramatically increased by CNHs at 5 µg mL−1
Fig. 2 TEM observations of cocultures without CNHs (A) and with
CNHs (B). (C) and (D) High magniﬁcations, corresponding to the white
frames in (A) and (B), showing the tight contact between the cells. (E)
High magniﬁcation corresponding to the white frame in (B) showing
CNHs in a cytoplasmic vesicle. (F) Control CNHs.
Fig. 3 Flow cytometry analysis of cellular viability of hMDMs exposed
to diﬀerent concentrations of CNHs. The two-way ANOVA followed by
the Bonferroni’s post-test was performed to determine the statistical
diﬀerences versus control cells and to compare the three CNH samples
with each other (***p < 0.001). LA&N: Late apoptotic and necrotic cells.
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(Fig. 5A). CNHs further increased the ALP activity of cocultures
after 14 days, while the ALP activity of hMSCs cocultured with
hMDM did not change in the absence of CNHs (Fig. 5B).
Several studies have reported that monocytes and macro-
phages directly regulate the osteogenic diﬀerentiation of MSCs
through a mechanism that involves cell contact, leading to the
production of OSM by the monocytes.31,33 In this study, OSM
levels in supernatants from hMSCs cocultured with hMDM
treated with and without CNHs were measured in order to
investigate whether OSM is one of the soluble factors increased
by CNHs during coculturing. The amount of OSM in the super-
natant with CNHs was 3 times higher than that of the control
experiment without CNHs (Fig. 6A). To measure how much the
OSM in the coculturing medium with CNHs aﬀects the induc-
tion of ALP, an OSM-neutralized antibody was added to hMSC
and hMDM cocultures at increasing concentrations (2, 20 and
200 ng ml−1) with and without CNHs. ALP activity was quanti-
fied after 7 days. The addition of the OSM-neutralizing anti-
body in the cocultured hMSCs and hMDMs with CNHs
prevented the ALP induction (Fig. 6B).
Table 1 List of genes up-regulated (A) and down-regulated (B) by adding CNHs to hMDMs after for 24 hours. Fold-change is represented by the
logarithmic ratio (log2 ratio) to the expression level in control
A
Gene name Systematic name
CNHs/CTRL
[rep.] Description
CCL4 NM_002984 1.472 Chemokine (C–C motif) ligand 4 (CCl4), mRNA
NFATC2 NM_173091 1.405 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (NFATC2),
transcript variant 2, mRNA
G0S2 NM_015714 1.372 G0/G1 switch 2 (G0S2), mRNA
ANKRD29 NM_173505 1.365 Ankyrin repeat domain 29 (ANKRD29), mRNA
CCL4L2 NM_001291470 1.343 Chemokine (C–C motif) ligand 4-like 2 (CCL4L2), transcript variant CCL4L2b2, mRNA
FBLN5 NM_006329 1.251 Fibulin 5 (FBLN5), mRNA
CCL3 NM_002983 1.229 Chemokine (C–C motif) ligand 3 (CCL3), mRNA
FBLIM1 NM_017556 1.167 Filamin binding LIM protein 1 (FBLIM1), transcript variant 1, mRNA
CXCL12 NM_199168 1.147 Chemokine (C–X–C motif) ligand 12 (CXCL12), transcript variant 1, mRNA
CTSZ ENST00000503833 1.135 Cathepsin Z (source: HGNC symbol; Acc: 2547)
NAF1 NM_138386 1.119 Nuclear assembly factor 1 ribonucleoprotein (NAF1), transcript variant 1, mRNA
FN1 NM_054034 1.099 Fibronectin 1 (FN1), transcript variant 7, mRNA
P2RY1 NM_002563 1.092 Purinergic receptor P2Y, G-protein coupled, 1 (P2RY1), mRNA
PARP15 NM_001113523 1.085 Poly(AOP-ribose) polymerase family, member 15 (PARP15), transcript variant 1, mRNA
CCL3L3 NM_001001437 1.024 Chemokine (C–C motif) ligand 3-like 3 (CCL3L3), mRNA
NEURL3 NM_001285486 1.000 Neuralized E3 ubiquitin protein ligase 3 (NEURL3), transcript variant 2, mRNA
B
IGF2BP1 NM_006548 −1.942 Insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1), transcript variant 1, mRNA
TIPARP NM_001184717 −1.459 TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), transcript variant 1, mRNA
SULF2 NM_018837 −1.291 Sulfatase 2 (SULF2), transcript variant 1, mRNA
CNR2 NM_001841 −1.240 Cannabinoid receptor 2 (macrophage) (CNR2), mRNA
CYP1B1 NM_000104 −1.151 Cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), mRNA
XYLT1 NM_022166 −1.139 Xylosyltransferase I (XYLT1), mRNA
FRY NM_023037 −1.130 Furry homolog (Drosophila) (FRY), mRNA
CTTNBP2 NM_033427 −1.106 Cortactin binding protein 2 (CTTNBP2), mRNA
LOC100128288 NR_024447 −1.077 Uncharacterized LOC100128288 (LOC100128288), long non-coding RNA
LOC100127886 AF090938 −1.070 Clone HQ0628 PRO0628 mRNA, complete cds.
LINC00926 NR_024433 −1.067 Long intergenic non-protein coding RNA 926 (LINC00926), long non-coding RNA
CLEC10A NM_182906 −1.030 C-type lectin domain family 10, member A (CLEC10A), transcript variant 1, mRNA
S100B NM_006272 −1.007 S100 calcium binding protein B (S100B), mRNA
PRRT1 NM_030651 −1.002 Proline-rich transmembrane protein 1 (PRRT1), mRNA
Table 2 The gene ontology of diﬀerent sets of genes from the microarray over-represented in macrophages cultured with CNHs versus macro-
phages cultured without CNHs
GO ID GO term P-value Genes
GO:2000403 Positive regulation of lymphocyte migration 4.65 × 10−7 CCL3 CCL4 CXCL12
GO:2000401 Regulation of lymphocyte migration 1.37 × 10−6 CCL3 CCL4 CXCL12
GO:2000503 Positive regulation of natural killer cell chemotaxis 5.12 × 10−6 CCL3 CCL4
GO:0072676 Lymphocyte migration 6.26 × 10−6 CCL3 CCL4 CXCL12
GO:0043270 Positive regulation of ion transport 8.20 × 10−6 CCL3 CCL4 CXCL12 P2RY1
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Discussion
In our previous studies, we found that CNHs accelerated bone
regeneration. In order to elucidate the mechanism of bone for-
mation, the behavior of macrophages in the presence of CNHs
and the eﬀect on mesenchymal stem cells were investigated in
cocultured cells.
According to the results of confocal microscopy, a large
number of CNHs were located in the hMDMs rather than
hMSCs. TEM observations confirmed that CNHs were present
in the subcellular compartments of the macrophages (i.e. lyso-
somes and endosomes). It was already reported that phagocy-
tic cells commonly internalize carbon nanohorns via
endocytosis,34 and accumulate them in the lysosomes.35 These
results definitely show that CNHs are taken up by macro-
phages with high selectivity, although the elucidation of the
precise process beyond the selective cellular internalization of
the CNHs, is an issue of future research.
CNHs did not increase cell apoptosis and necrosis at least
up to 50 µg mL−1 as shown by flow cytometry analyses,
although CNHs were highly accumulated into the lysosomes.
Indeed, many researchers have reported that the cytotoxicity of
CNHs was very low.6,29,35,36 However, a high uptake level of
CNHs in RAW 264.7, a well-known murine macrophage cell
line, seemed to generate reactive oxygen species (ROS), lysoso-
mal membrane destabilization, cell apoptosis and necrosis.35
Russier et al. reported that human macrophages appeared less
responsive to carbon nanomaterials in comparison with
murine macrophage. This work suggests that hMDMs likely
respond to CNHs less than murine macrophage. Our results
are similar to those obtained with other types of nano-
materials and nanoparticles, designed for diﬀerent appli-
cations (i.e. as contrast agents for imaging or for drug
delivery), which resulted immune compatible or could exert
Fig. 4 qPCR analysis of relative expression levels of CCL3, CCL4
CXCL12 cytokines for hMDMs cultured with or without CNHs for
24 hours. ***p < 0.001.
Fig. 5 ALP activity of hMSC alone or cocultured hMDMs and hMSCs
with or without CNHs after 7 days (A) and ALP activity cocultured after
14 days (B). ***p < 0.001.
Fig. 6 (A) OSM levels in the supernatants of cocultured hMDMs and
hMSCs with or without CNHs. (B) ALP activity was quantiﬁed at 7 days
after the OSM neutralizing antibody was added to the cocultures with or
without CNHs. *p < 0.05.
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an immune specific action depending on their composition
and surface coating.37,38
Microarray analysis indicates that chemokine-related genes,
including CCL3, CCL4, and CXCL12, were expressed signifi-
cantly higher in hMDMs treated with CNHs than without
CNHs. GO analysis suggests that these up-regulated genes
regulate lymphocyte migration. Furthermore, it has been
reported that these chemokines are involved not only in immu-
noregulatory and inflammatory processes but also in tissue
repair.39 For example, CXCL12 was reported to play a role in
the maintenance, survival, and osteogenic capacity of imma-
ture bone marrow stromal stem cell populations.40 Our results
clearly indicate that CNHs might be promising regulators for a
variety of immune system reactions without triggering any
cytotoxicity.
In order to elucidate the relation between macrophages
with internalized CNHs and bone formation, human macro-
phage and mesenchymal stem cells were cocultured in the
presence of CNHs (Fig. 5). CNHs dramatically increased the
ALP activity of the cocultures. According to the TEM obser-
vations (Fig. 2C and D), hMDMs have the possibility to com-
municate with hMSCs via molecular signaling because of the
tight contact observed between these two types of cells. Several
studies have reported that macrophages directly regulate osteo-
genic diﬀerentiation of MSCs through a mechanism that
involves cell contact leading to the production of Oncostatin M
by monocytes and STAT3 signaling in MSCs.31,33 OSM, which
is produced by activated monocytes, is a multifunctional cyto-
kine that influences the growth and diﬀerentiation of several
cell types.32,41 In vitro studies on osteoblastic models have
demonstrated that OSM stimulates osteogenic diﬀerentiation
in MSCs 42 and inhibits adipogenic diﬀerentiation of hMSCs.43
In support of these studies, we found that OSM was increased
in the medium of cocultured hMSCs and hMDMs. Moreover,
OSM was significantly increased in the presence of CNHs
(Fig. 6A). An OSM-neutralizing antibody prevented ALP induc-
tion in the presence of CNHs but had no eﬀect on ALP activity
without CNHs (Fig. 6B). These data suggested that ALP activity
is enhanced by OSM produced during coculturing hMDMs
and hMSCs in the presence of CNHs.
Even with the addition of an OSM-neutralizing antibody,
ALP activity was still higher than control. Therefore there
might be other factors involved in the increase of ALP activity.
For instance, several studies have reported that CXCL12 pro-
motes the growth, survival, and development of hMSCs,44 and
bone formation.12,45 Further studies must be performed to
find the other factors increasing bone formation by CNHs.
However, these data suggested that OSM is one of the possible
factors to induce hMSC diﬀerentiation into osteoblasts in
cocultures with hMDM loaded with CNHs.
The immune cell responses to biomaterial interactions and
subsequent eﬀects of factors released by immune cells on
osteoblastic cells are important.46 Few studies with diﬀerent
biomaterials have described bone formation via macrophage
activation. For example, a recent systematic review of dental
implants reported that over 90% of research in this area
focused primarily on the in vitro behavior of osteoblasts on
implant surfaces while only a small percentage (roughly 10%)
was dedicated to immune cells.47 Almost all of the studies
about carbon nanomaterials and bone also focused mainly on
osteoblasts. For instance, Shimizu et al. showed that multi-
walled carbon nanotubes (MWCNTs) can promote bone for-
mation by interacting with osteoblasts by accumulating
calcium which adhered to MWCNTs.48 In an in vitro study Saito
et al. found that CNTs are suitable to stimulate osteoblast
functions.49 Misra et al. reported that CNHs and graphene
oxide inside polymeric materials are able to enhance osteo-
blast functions and cellular interactions.13,50 As far as we know,
there have been no studies investigating the mechanisms of
bone formation using carbon nanomaterials with the focus on
the relationship between macrophages, mesenchymal stem
cells and these nanomaterials.
This study demonstrates one of the possible mechanisms
for bone formation with CNHs. Our findings may be an
important milestone and inspire a new design of therapeutic
materials for bone regeneration using CNHs such as dental
implant and osteoblast cell culture scaﬀolds.
Experimental section
Preparation of CNH dispersion
CNHs were produced by CO2 laser ablation of graphite without
the metal catalysts.28 CNHs were oxidized with air by increas-
ing the temperature at 1 °C min−1 from room temperature to
500 °C, followed by cooling.51 Functionalization of CNHs with
Alexa488-BSA (Alexa-BSA-CNHs) was performed as previously
described.36 The CNHs or Alexa-BSA-CNHs were dispersed in
bovine serum albumin (BSA) at a concentration of 1 mg mL−1.
The general medium consisted of DMEM Glutamax media
(Gibco) supplemented with 10% heat-inactivated fetal bovine
serum (FBS: MP Biomedicals, OH) and streptomycin/penicillin
(Gibco). The CNH dispersions by BSA were diluted with the
general medium by serial dilution (0.5, 5.0, 50 µg mL−1) and
used for human hMDM culture and cocultures of hMDMs and
hMSCs.
Cell culture
Ethical approval for the use of peripheral blood from healthy
donors was obtained from the Hokkaido University Graduate
School of Dental Medicine Ethics Committee (No. 2014-6).
Whole blood used in this study was obtained from donors
with written informed consent. Peripheral blood mononuclear
cells (PBMCs) from healthy adult donors were collected by cen-
trifugation over a Ficoll-Histpaque-1077 (Sigma, MO). CD14+
cells were magnetically labeled with CD14 microbeads and
positively selected by MACS Technology (Miltenyi Biotec,
Germany). The medium for PBMCs consisted of RPMI 1640
(Sigma) including 10% heat inactivated FBS, 10 mM HEPES
(Lonza) and streptomycin/penicillin. PBMCs were cultured at
37 °C, 5% CO2, in 12-well plates at a density of 3 × 10
6 cells per
well in the medium for PBMC for one day.52 hMDMs were
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obtained by culturing PBMCs in the medium supplemented
with 12.5 ng ml−1 of a macrophage colony stimulating factor
(M-CSF; ImmunoTools) for an additional 6 days. hMSCs were
commercially purchased (Product No. PT-2501, Lonza, Switzer-
land). hMSCs were maintained in a general medium and used
between passages 3 and 8. Four hours after seeding, each
medium was replaced with the general medium with and
without CNHs.
Confocal laser scanning electron microscopy observation
hMSCs were subcultured and stained by the Cell Tracker Red
CMPTX dye (Molecular Probes) one day before seeding. Each
cell was seeded on an 8-well cell culture slide (Falcon) in
200 µL medium at a density of 5 × 104 cells per mL in the
general medium for hMSCs or 5 × 105 cells per mL for hMDMs
in the medium for PBMCs. For the cocultures, hMSCs were
seeded at first and then hMDMs were seeded on them. Four
hours after seeding, each medium was replaced with the
medium with and without Alexa-BSA-CNHs (5 µg mL−1). After
24 hours, the cellular uptake of CNHs was observed using an
inverted microscope (Nikon Ti-E, Japan) with a confocal laser
scanning system (Nikon A1, Japan).
Transmission electron microscopy observation
hMSCs were seeded at first on glass coverslips in 24-well plates
at a density of 5000 cells per well and hMDMs were seeded on
them at a density of 50 000 cells per well and cultured with
and without CNHs (5 µg mL−1) for 24 hours. For TEM
samples, polymerized blocks with embedded cells were pre-
pared as previously described.52 Afterwards, the glass cover-
slips were removed from the polymerized block surface. A
cube-shaped sample was taken from the capsule and a resin
was applied to the surface. Then, the cube was laid on its side
and cut into ultrathin sections. The ultrathin sections were
obtained using an ultramicrotome (Leica) with a diamond knife
(DiATOME). The ultrathin sections were examined by TEM
(JEM1400 80 V and Titan cubed G2 60-300 operated at 60 kV).
Detection of apoptotic cells
hMDMs were seeded in 98-well plates (1.5 × 105 cells per well)
and cultured with each CNH medium (0, 0.5, 5.0, 50 µg mL−1)
while DMSO 10% was used as positive control for cell death.
Flow cytometry analysis was carried out as previously
reported,52 using APC-Annexin V (AnnV; BD Pharmingen
550475) and propidium iodide (PI, 0.2 µg mL−1; Sigma-
Aldrich) in a calcium containing buﬀer. The percentage of live
(AnnV−/PI−), early apoptotic (AnnV+/PI−) and late apoptotic/
necrotic (AnnV+/PI+) and AnnV−/PI+) cells was determined by
acquiring at least 25 000 events using a FACS Flow Cytometer
(Gallios, Beckman Coulter) and by analyzing the data on
CD14+ hMDM (FITC-Mouse anti-Human CD14, Clone M5E2,
BD Pharmingen 555397) gated populations with FlowJo
software.
Microarray analysis
The procedure of DNA microarray analysis has been described
in detail previously.53 Briefly, the total RNA of hMDMs cul-
tured for one day with CNHs (5 µg mL−1) was extracted with
ISOGEN (Nippon Gene, Tokyo, Japan) according to the manu-
facturer’s instructions. mRNA was amplified with the Animo
Allyl MessageAmp II aRNA amplification kit (Thermo Fisher
Scientific, Waltham, MA, USA) and labeled with Cy3 or Cy5.
The global gene expression analysis was performed with the
Whole Human Genome Microarray Kit 4 × 44 K (Agilent, Santa
Clara, CA, USA). The fluorescent intensity of Cy3 and Cy5 in
each spot was scanned with a GenePix 4000B and detected
with a GenePix Pro (Molecular Devices, Sunnyvale, CA, USA).
Gene expression data obtained from fluorescent intensity were
globally normalized, and locally weighted scatter plot smooth-
ing adjustment was applied. The DNA microarray experiment
was conducted twice, and genes whose expression level ratios
from two experiments were less than double were identified as
valid data. The extracted up-regulated and down-regulated
genes were placed in Gene Ontology bioprocess categories
using the PANTHER gene expression analysis/compare gene
lists.
Real-time polymerase chain reaction
Total RNA was extracted from one day hMDM cultures using
ISOGEN (Nippon gene). First-strand cDNA was synthesized
from 500 ng total RNA using Primescript (Takara). The real-
time polymerase chain reaction (PCR) contained 10 ng reverse
transcribed total RNA, 400 nM primers (Table S1†), and SYBR
Premix Ex Taq (Takara). Quantitative PCRs (qPCRs) were
carried out on a StepOnePlus RealTime PCR System (Applied
Biosystems). Relative quantification was made against serial
dilution of GAPDH cDNA which was used as a house-keeping
gene.
Measurement of ALP activity
hMSCs were seeded in 24-well plates at a density of 5000 cells
per well and hMDMs were seeded on them at a density of
50 000 cells per well for coculture. After 7 and 14 days of cell
culture with and without CNHs (0.5, 5, 50 µg mL−1), the
amount of the ALP activity in the cells was measured as pre-
viously reported.22
Measurement of OSM levels and ALP activity with OSM
neutralizing antibody
After a 7 day coculture, the OSM levels in supernatants were
measured using the Human OSM DuoSet (R&D systems). The
OSM neutralizing antibody was added to the cocultures at
increasing concentrations (2, 20, 200 ng ml−1) in the general
medium and ALP activity was quantified after additional
7 days.
Statistical analysis
All data are presented ± standard error of the mean (SEM).
Statistical analyses were performed using GraphPad software
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and two-way ANOVA followed by Bonferroni’s post-test or Stu-
dent’s t test. All p values <0.05 were considered significant.
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